on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Disclosure on Avadel Pharmaceuticals
The Vanguard Group, Inc. has made a disclosure under the Irish Takeover Panel's Rule 8.3 regarding its interests in Avadel Pharmaceuticals plc. As of November 13, 2025, Vanguard holds 5,525,214 ordinary shares, representing 5.67% of Avadel's securities.
In terms of recent transactions, Vanguard purchased 1,155 shares and sold 195 at a unit price of 19.24 USD per share. No derivative transactions or other dealings were reported.
The disclosure indicates no indemnity, option arrangements, or agreements related to voting rights or future acquisitions. The document provides transparency on Vanguard's position in Avadel amidst any ongoing or potential takeovers.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news